KR20190066030A - Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용 - Google Patents

Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용 Download PDF

Info

Publication number
KR20190066030A
KR20190066030A KR1020197012272A KR20197012272A KR20190066030A KR 20190066030 A KR20190066030 A KR 20190066030A KR 1020197012272 A KR1020197012272 A KR 1020197012272A KR 20197012272 A KR20197012272 A KR 20197012272A KR 20190066030 A KR20190066030 A KR 20190066030A
Authority
KR
South Korea
Prior art keywords
xaa
amino acid
misc
feature
naturally occurring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197012272A
Other languages
English (en)
Korean (ko)
Inventor
프랭크 웬-치 리
콴인 카렌 린
여우-핑 차오
중-추안 호
Original Assignee
브림 바이오테크놀로지, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브림 바이오테크놀로지, 인코퍼레이티드 filed Critical 브림 바이오테크놀로지, 인코퍼레이티드
Priority to KR1020237039829A priority Critical patent/KR20230169375A/ko
Publication of KR20190066030A publication Critical patent/KR20190066030A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020197012272A 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용 Ceased KR20190066030A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237039829A KR20230169375A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405522P 2016-10-07 2016-10-07
US62/405,522 2016-10-07
PCT/US2017/048340 WO2018067244A1 (en) 2016-10-07 2017-08-24 Compositions comprising pedf-derived short peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237039829A Division KR20230169375A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용

Publications (1)

Publication Number Publication Date
KR20190066030A true KR20190066030A (ko) 2019-06-12

Family

ID=61831898

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197012272A Ceased KR20190066030A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용
KR1020237039829A Ceased KR20230169375A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237039829A Ceased KR20230169375A (ko) 2016-10-07 2017-08-24 Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용

Country Status (10)

Country Link
US (1) US11760784B2 (OSRAM)
EP (1) EP3596104A4 (OSRAM)
JP (2) JP7573967B2 (OSRAM)
KR (2) KR20190066030A (OSRAM)
CN (1) CN110312732A (OSRAM)
AU (2) AU2017340245B2 (OSRAM)
EA (1) EA037698B1 (OSRAM)
IL (1) IL265796B2 (OSRAM)
TW (1) TWI878203B (OSRAM)
WO (2) WO2018067244A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7494122B2 (ja) * 2018-04-08 2024-06-03 ブリム バイオテクノロジー インク 変形性関節症の治療におけるｐｅｄｆ由来短鎖ペプチドの使用
CN113038929A (zh) * 2018-04-08 2021-06-25 全福生物科技股份有限公司 Pedf衍生的短肽在肌腱愈合中的应用
CN112566621A (zh) * 2018-05-04 2021-03-26 全福生物科技股份有限公司 用于促进睑板腺再生的pedf衍生肽及其用途
CN111632128B (zh) * 2019-02-14 2022-07-05 三凡生技研发股份有限公司 短链胜肽组合物在预防或治疗干眼症的应用
TWI759610B (zh) * 2019-06-27 2022-04-01 晶碩光學股份有限公司 具有角膜修護功能的眼用產品
WO2021035515A1 (en) * 2019-08-27 2021-03-04 Tsao Yeou Ping Short synthetic peptide and their uses for treating retinal degenerative diseases and/or tissue injuries
TWI744683B (zh) * 2019-08-27 2021-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其治療視網膜退化性疾病和/或組織損傷的用途
IL291929A (en) * 2019-10-06 2022-06-01 Brim Biotechnology Inc Compositions comprising pedf-derived short peptides (pdsp) and uses thereof
CN112206312A (zh) * 2020-11-19 2021-01-12 北京大学第三医院（北京大学第三临床医学院） 一种包含pedf的用于治疗干眼的药物组合物
CN115364199A (zh) * 2021-05-19 2022-11-22 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途
IL317620A (en) * 2022-06-13 2025-02-01 Brim Biotechnology Inc Preparations containing short peptides derived from PEDF for the treatment of dry eye diseases
TW202400628A (zh) * 2022-06-24 2024-01-01 全福生物科技股份有限公司 用於治療神經營養性角膜炎疾病之包含pedf衍生短肽之組合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
JP2007509984A (ja) * 2003-10-29 2007-04-19 ザ・ジョンズ・ホプキンス・ユニバーシティ 色素上皮由来因子、その新規な生物活性及びその使用方法
CA2559436A1 (en) * 2004-03-12 2005-09-29 Genvec, Inc. Materials for treating vascular leakage in the eye
WO2007095350A2 (en) * 2006-02-15 2007-08-23 Yale University Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
WO2009134339A2 (en) * 2008-04-29 2009-11-05 Monsanto Technology, Llc Genes and uses for plant enhancement
CA2776748A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
EP2508196B1 (en) * 2011-03-23 2018-09-26 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing
TWI554521B (zh) * 2011-10-19 2016-10-21 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 色素上皮衍生因子衍生之多胜肽於治療禿髮和／或毛髮脫色之用途
EP3339317A1 (en) * 2012-08-09 2018-06-27 MacKay Memorial Hospital Use of pedf-derived polypeptides for promoting muscle regeneration
EP2897976B1 (en) * 2012-09-19 2017-08-09 Mackay Memorial Hospital Use of pedf-derived peptides for preventing and/or ameliorating skin aging
US9777048B2 (en) * 2012-09-20 2017-10-03 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating osteoarthritis
WO2015038891A2 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional peptide analogs of pedf

Also Published As

Publication number Publication date
JP2019533722A (ja) 2019-11-21
TW201822785A (zh) 2018-07-01
JP2022185042A (ja) 2022-12-13
KR20230169375A (ko) 2023-12-15
IL265796B1 (en) 2024-10-01
AU2017340245B2 (en) 2022-07-21
WO2018067217A3 (en) 2019-05-02
IL265796A (en) 2019-06-30
JP7573967B2 (ja) 2024-10-28
US11760784B2 (en) 2023-09-19
WO2018067217A2 (en) 2018-04-12
EA037698B1 (ru) 2021-05-12
EP3596104A4 (en) 2021-02-17
AU2022204557A1 (en) 2022-07-21
EA201990885A1 (ru) 2019-08-30
TWI878203B (zh) 2025-04-01
US20190248859A1 (en) 2019-08-15
IL265796B2 (en) 2025-02-01
AU2017340245A1 (en) 2019-05-23
EP3596104A1 (en) 2020-01-22
CN110312732A (zh) 2019-10-08
WO2018067244A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
KR20190066030A (ko) Pedf-유래 짧은 펩타이드를 포함하는 조성물 및 그것의 사용
Yang et al. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling
Yang et al. 0.005% preservative-free latanoprost induces dry eye-like ocular surface damage via promotion of inflammation in mice
Feng et al. Cynaroside protects the blue light-induced retinal degeneration through alleviating apoptosis and inducing autophagy in vitro and in vivo
JP6612247B2 (ja) 眼の感染症および疾患を処置するための組成物および方法
US20240123032A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
Lin et al. Serine protease inhibitor A3K suppressed the formation of ocular surface squamous metaplasia in a mouse model of experimental dry eye
US20210386837A1 (en) Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
Chaudhari et al. Rodent models for dry eye syndrome: Standardization using benzalkonium chloride and scopolamine hydrobromide
Li et al. Effects of topical mucolytic agents on the tears and ocular surface: a plausible animal model of mucin-deficient dry eye
Li et al. Expression and role of nucleotide-binding oligomerization domain 2 (NOD2) in the ocular surface of murine dry eye
Chen et al. Aim2 deficiency ameliorates lacrimal gland destruction and corneal epithelium defects in an experimental dry eye model
Jin et al. Anti-inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye
AU2019262664B2 (en) PEDF-derived peptides for promoting meibomian gland regeneration and uses thereof
JP2022542889A (ja) ドライアイ疾患のためのｔｓｇ６ポリペプチドフラグメント
TWI796875B (zh) 一種醫藥組合物用於製備眼表損傷之藥物的用途
CN107428805A (zh) 短合成肽及其治疗和/或预防干眼症的用途
US20180256690A1 (en) Protection and sealing of the ocular surface barrier by clusterin
Fernandez-Robredo et al. Azithromycin reduces inflammation in a rat model of acute conjunctivitis
HK1241379B (zh) 短合成肽及其治疗和/或预防乾眼症的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190426

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200814

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220824

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230620

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220824

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I